
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
Keywords: [3H]-PAF; platelet activating factor; DIACOR; Diabetes and Combined Lipid Therapy Regimen; FIELD; Fenofibrate Intervention and Event Lowering in Diabetes; HDL-C; high-density lipoprotein cholesterol; HRP; horseradish-peroxidase; ICAM-1; intercellular adhe